Changchun High-Tech Industry (Group) Past Earnings Performance
Past criteria checks 3/6
Changchun High-Tech Industry (Group) has been growing earnings at an average annual rate of 21.4%, while the Pharmaceuticals industry saw earnings growing at 9.2% annually. Revenues have been growing at an average rate of 17.5% per year. Changchun High-Tech Industry (Group)'s return on equity is 18.6%, and it has net margins of 30.3%.
Key information
21.4%
Earnings growth rate
19.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 17.5% |
| Return on equity | 18.6% |
| Net Margin | 30.3% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Changchun High-Tech Industry (Group) makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 14,966 | 4,534 | 5,095 | 1,810 |
| 31 Dec 23 | 14,566 | 4,532 | 4,972 | 1,723 |
| 30 Sep 23 | 13,663 | 4,288 | 4,739 | 1,593 |
| 30 Jun 23 | 12,964 | 4,181 | 4,668 | 1,461 |
| 31 Mar 23 | 12,430 | 3,859 | 4,562 | 1,459 |
| 01 Jan 23 | 12,627 | 4,141 | 4,645 | 1,358 |
| 30 Sep 22 | 12,154 | 4,075 | 4,465 | 1,248 |
| 30 Jun 22 | 11,615 | 3,954 | 4,251 | 1,133 |
| 31 Mar 22 | 11,440 | 4,021 | 3,999 | 983 |
| 01 Jan 22 | 10,747 | 3,757 | 3,707 | 885 |
| 30 Sep 21 | 10,416 | 3,934 | 3,355 | 728 |
| 30 Jun 21 | 9,623 | 3,660 | 3,191 | 639 |
| 31 Mar 21 | 9,197 | 3,379 | 3,165 | 562 |
| 31 Dec 20 | 8,577 | 3,047 | 3,066 | 475 |
| 30 Sep 20 | 8,329 | 2,795 | 3,082 | 413 |
| 30 Jun 20 | 7,899 | 2,358 | 3,093 | 363 |
| 31 Mar 20 | 7,260 | 1,952 | 3,004 | 304 |
| 31 Dec 19 | 7,374 | 1,775 | 2,977 | 370 |
| 30 Sep 19 | 6,679 | 1,408 | 2,907 | 339 |
| 30 Jun 19 | 6,017 | 1,185 | 2,653 | 329 |
| 31 Mar 19 | 6,118 | 1,161 | 2,669 | 359 |
| 31 Dec 18 | 5,375 | 1,006 | 2,459 | 328 |
| 30 Sep 18 | 5,594 | 1,014 | 2,317 | 372 |
| 30 Jun 18 | 5,251 | 926 | 2,113 | 483 |
| 31 Mar 18 | 4,393 | 728 | 1,959 | 373 |
| 31 Dec 17 | 4,102 | 662 | 1,862 | 289 |
| 30 Sep 17 | 3,353 | 592 | 1,705 | 178 |
| 30 Jun 17 | 3,222 | 554 | 1,687 | 0 |
| 31 Mar 17 | 2,995 | 506 | 1,534 | 0 |
| 31 Dec 16 | 2,897 | 485 | 1,411 | 0 |
| 30 Sep 16 | 2,877 | 467 | 1,348 | 0 |
| 30 Jun 16 | 2,603 | 423 | 1,272 | 0 |
| 31 Mar 16 | 2,526 | 411 | 1,211 | 0 |
| 31 Dec 15 | 2,402 | 384 | 1,159 | 0 |
| 30 Sep 15 | 2,623 | 446 | 1,116 | 0 |
| 30 Jun 15 | 2,460 | 388 | 1,101 | 0 |
| 31 Mar 15 | 2,336 | 349 | 1,084 | 0 |
| 31 Dec 14 | 2,262 | 318 | 1,101 | 0 |
| 30 Sep 14 | 1,921 | 250 | 1,031 | 0 |
| 30 Jun 14 | 1,960 | 240 | 1,010 | 0 |
| 31 Mar 14 | 2,005 | 279 | 991 | 0 |
| 31 Dec 13 | 2,049 | 284 | 1,015 | 0 |
| 30 Sep 13 | 1,995 | 341 | 967 | 0 |
| 30 Jun 13 | 1,900 | 356 | 943 | 0 |
Quality Earnings: 000661 has high quality earnings.
Growing Profit Margin: 000661's current net profit margins (30.3%) are lower than last year (31%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 000661's earnings have grown significantly by 21.4% per year over the past 5 years.
Accelerating Growth: 000661's earnings growth over the past year (17.5%) is below its 5-year average (21.4% per year).
Earnings vs Industry: 000661 earnings growth over the past year (17.5%) exceeded the Pharmaceuticals industry -1.1%.
Return on Equity
High ROE: 000661's Return on Equity (18.6%) is considered low.